Table 2.

Base-line anticholinergic use and cognitive decline over the 4-year follow-up period

	Model 0		Model 1		Model 2
	OR [CI95]	p-value	OR [CI95]	p-value	OR [CI95]	p-value
WOMEN (n=4128*)
Δ Isaacs total ≤−6	1.47 [1.16–1.86]	0.002	1.44 [1.13–1.83]	0.003	1.41 [1.11–1.79]	0.006
ΔBenton ≤ −2	1.13 [0.89–1.43]	0.33
ΔTMT A ≥ 16	1.05 [0.78–1.42]	0.73
ΔTMT B ≥ 35	0.98 [0.73–1.31]	0.88
ΔMMSE ≤ −2	1.26 [1.00–1.60]	0.05	1.25 [0.99–1.58]	0.07	1.22 [0.96–1.55]	0.10
MEN (n=2784*)
ΔIsaacs30 ≤ −6	1.03 [0.67–1.59]	0.89
ΔBenton ≤ −2	1.70 [1.13–2.56]	0.01	1.68 [1.11–2.53]	0.01	1.63 [1.08–2.47]	0.02
ΔTMT A ≥ 16	0.84 [0.48–1.46]	0.53
ΔTMT B ≥ 35	1.61 [0.98–2.64]	0.06	1.58 [0.96–2.62]	0.07	1.47 [0.89–2.44]	0.14
ΔMMSE ≤ −2	1.39 [0.92–2.09]	0.12

^*Except for TMT which concerned 3447 women and 2269 men

Model 0: adjusted for centre, age, education, and baseline cognitive performance.

Model 1: adjusted for centre, age, education, base-line cognitive performance, BMI, alcohol, tobacco and caffeine intake, mobility, hypercholesterolemia, ApoE, diabetes, asthma, (for men and women) as well as HRT for women.

Model 2: adjusted for all the covariates in model 1, plus depression, ischemic pathologies, Parkinson’s disease and hypertension (for men and women)